Comparison of Dosimetric Performance among Commercial Quality Assurance Systems for Verifying Pretreatment Plans of Stereotactic Body Radiotherapy Using Flattening-Filter-Free Beams

The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pr...

Full description

Saved in:
Bibliographic Details
Published inJournal of Korean medical science Vol. 31; no. 11; pp. 1742 - 1748
Main Authors Chung, Jin-Beom, Kang, Sang-Won, Eom, Keun-Yong, Song, Changhoon, Choi, Kyoung-Sik, Suh, Tae Suk
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Academy of Medical Sciences 01.11.2016
대한의학회
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I'mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan.
AbstractList The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I'mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan.The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I'mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan.
The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I’mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan. KCI Citation Count: 0
The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I'mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan.
The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I’mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam ® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan.
Author Song, Changhoon
Kang, Sang-Won
Suh, Tae Suk
Choi, Kyoung-Sik
Chung, Jin-Beom
Eom, Keun-Yong
AuthorAffiliation 3 Department of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea
1 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea
4 Department of Radiation Oncology, SAM Anyang Hospital, Anyang, Korea
2 Research Institute of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea
AuthorAffiliation_xml – name: 1 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea
– name: 4 Department of Radiation Oncology, SAM Anyang Hospital, Anyang, Korea
– name: 2 Research Institute of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea
– name: 3 Department of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea
Author_xml – sequence: 1
  givenname: Jin-Beom
  orcidid: 0000-0003-2668-3906
  surname: Chung
  fullname: Chung, Jin-Beom
  organization: Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea
– sequence: 2
  givenname: Sang-Won
  orcidid: 0000-0002-6376-7757
  surname: Kang
  fullname: Kang, Sang-Won
  organization: Research Institute of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea
– sequence: 3
  givenname: Keun-Yong
  orcidid: 0000-0003-3650-1133
  surname: Eom
  fullname: Eom, Keun-Yong
  organization: Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea
– sequence: 4
  givenname: Changhoon
  orcidid: 0000-0002-0714-8775
  surname: Song
  fullname: Song, Changhoon
  organization: Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea
– sequence: 5
  givenname: Kyoung-Sik
  orcidid: 0000-0001-6247-4314
  surname: Choi
  fullname: Choi, Kyoung-Sik
  organization: Department of Radiation Oncology, SAM Anyang Hospital, Anyang, Korea
– sequence: 6
  givenname: Tae Suk
  orcidid: 0000-0002-3057-1627
  surname: Suh
  fullname: Suh, Tae Suk
  organization: Research Institute of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27709851$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002164548$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9Ustu1DAUjVARfcAfIOQlLDLYie0kLJCmQwcqVWLog63lca5bd-J4sB2kfFj_D2emVMAC6Ur3Sj4P-_ocZwe96yHLXhM8K0vK399vbJgVmPBZSWYkVUWLZ9kRYU2d85JVB2nGhOR1U9LD7DiEe4wLxoryRXZYVBVuakaOsoeFs1vpTXA9chp9csFYiN4otAKvnbeyV4Ckdf0tSlALXhnZoW-D7Ewc0TyEwe8gV2OIYANKHPQdvNGjSZSVT2Igo4U-olUn-zC5XEXw4KJUMfmcunZEl7I1Lt6Bl9sR3YSJuuxkjNCnMV-aLjHypQdApyBteJk917IL8Oqxn2Q3y7PrxZf84uvn88X8IleUFjFnCnTNWqZ5yzHXlKqqrlkl1wAVp03ZEo31ek2hBI5lVcmmTitTnCtd0CKt6iR7t9ftvRYbZYSTZtdvndh4Mb-8PhekqGpOccJ-3GO3w9pCq9KLvezE1hsr_bhj_n3Sm7uk81MwzHiBWRJ4-yjg3Y8BQhTWBAVd2hq4IQhSl7RpaM0mrzd_ej2Z_P7XBKB7gPIuBA_6CUKwmOIjpviIKT6iJIKkSvFJtA__0JSJMho33dh0_yf_AldY0UY
CitedBy_id crossref_primary_10_1016_j_rpor_2019_07_007
crossref_primary_10_14316_pmp_2017_28_1_16
crossref_primary_10_1016_j_ejmp_2024_104822
crossref_primary_10_1088_2057_1976_ad2630
crossref_primary_10_1002_acm2_14352
crossref_primary_10_1016_j_radphyschem_2021_109739
crossref_primary_10_1016_j_ijrobp_2022_10_017
crossref_primary_10_1002_acm2_13645
crossref_primary_10_1007_s40846_018_0420_z
Cites_doi 10.1016/j.ejmp.2013.05.004
10.1088/0031-9155/55/8/003
10.1515/raon-2015-0021
10.3938/jkps.67.1672
10.1088/0031-9155/52/4/023
10.1120/jacmp.v11i4.3164
10.1186/1748-717X-6-113
10.1118/1.3533900
10.1118/1.2134929
10.1016/j.ijrobp.2010.10.002
10.1118/1.3685461
10.1120/jacmp.v13i4.3736
10.1120/jacmp.v12i2.3251
10.1016/j.radonc.2013.08.048
10.1120/jacmp.v14i6.4460
10.1016/j.zemedi.2010.07.003
10.1120/jacmp.v16i6.5728
10.1118/1.3431994
10.14316/pmp.2014.25.4.210
10.1016/j.ejmp.2015.05.016
10.1118/1.1591194
10.1186/1748-717X-5-110
10.3938/jkps.64.1207
10.1002/jmrs.78
ContentType Journal Article
Copyright 2016 The Korean Academy of Medical Sciences. 2016
Copyright_xml – notice: 2016 The Korean Academy of Medical Sciences. 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.3346/jkms.2016.31.11.1742
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1598-6357
EndPage 1748
ExternalDocumentID oai_kci_go_kr_ARTI_1278640
PMC5056205
27709851
10_3346_jkms_2016_31_11_1742
Genre Journal Article
Comparative Study
GrantInformation_xml – fundername: ;
  grantid: HI15C0638
– fundername: ;
  grantid: 2014R1A2A1A10050270
GroupedDBID ---
29K
2WC
3O-
5-W
53G
5GY
8JR
8XY
9ZL
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
CS3
D-I
DIK
DU5
E3Z
EBS
EF.
EJD
F5P
FRP
GROUPED_DOAJ
GX1
HYE
KQ8
M48
O5R
O5S
OK1
OVT
PGMZT
RNS
RPM
TR2
W2D
XSB
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
ID FETCH-LOGICAL-c442t-5cef85d5f6d606f44c78857abee76493d1f0fbb4e3e60a77a98101c66cf242523
IEDL.DBID M48
ISSN 1011-8934
1598-6357
IngestDate Sun Mar 09 07:51:18 EDT 2025
Thu Aug 21 14:09:56 EDT 2025
Fri Jul 11 12:06:47 EDT 2025
Thu Apr 03 06:56:33 EDT 2025
Thu Apr 24 23:02:42 EDT 2025
Tue Jul 01 01:44:57 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Stereotactic Body Radiotherapy
Delivery Quality Assurance
Pretreatment Verification
Language English
License http://creativecommons.org/licenses/by-nc/4.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c442t-5cef85d5f6d606f44c78857abee76493d1f0fbb4e3e60a77a98101c66cf242523
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Jin-Beom Chung and Sang-Won Kang contributed equally to this work.
G704-000345.2016.31.11.007
ORCID 0000-0001-6247-4314
0000-0003-3650-1133
0000-0002-0714-8775
0000-0002-6376-7757
0000-0002-3057-1627
0000-0003-2668-3906
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3346/jkms.2016.31.11.1742
PMID 27709851
PQID 1834994850
PQPubID 23479
PageCount 7
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_1278640
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5056205
proquest_miscellaneous_1834994850
pubmed_primary_27709851
crossref_primary_10_3346_jkms_2016_31_11_1742
crossref_citationtrail_10_3346_jkms_2016_31_11_1742
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-11-01
PublicationDateYYYYMMDD 2016-11-01
PublicationDate_xml – month: 11
  year: 2016
  text: 2016-11-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Journal of Korean medical science
PublicationTitleAlternate J Korean Med Sci
PublicationYear 2016
Publisher The Korean Academy of Medical Sciences
대한의학회
Publisher_xml – name: The Korean Academy of Medical Sciences
– name: 대한의학회
References Rinaldin (10.3346/jkms.2016.31.11.1742_ref26) 2014; 30
Kim (10.3346/jkms.2016.31.11.1742_ref5) 2011; 22
Chung (10.3346/jkms.2016.31.11.1742_ref13) 2015; 16
Iftimia (10.3346/jkms.2016.31.11.1742_ref23) 2010; 11
Son (10.3346/jkms.2016.31.11.1742_ref7) 2015; 49
Chandraraj (10.3346/jkms.2016.31.11.1742_ref31) 2011; 12
Kim (10.3346/jkms.2016.31.11.1742_ref4) 2014; 64
Cashmore (10.3346/jkms.2016.31.11.1742_ref11) 2011; 80
Kry (10.3346/jkms.2016.31.11.1742_ref9) 2010; 55
Lang (10.3346/jkms.2016.31.11.1742_ref16) 2012; 39
Nelms (10.3346/jkms.2016.31.11.1742_ref22) 2007; 8
Elith (10.3346/jkms.2016.31.11.1742_ref8) 2014; 61
Alvarez-Moret (10.3346/jkms.2016.31.11.1742_ref21) 2010; 5
Thomas (10.3346/jkms.2016.31.11.1742_ref2) 2005; 32
Ezzell (10.3346/jkms.2016.31.11.1742_ref3) 2003; 30
Masi (10.3346/jkms.2016.31.11.1742_ref27) 2011; 38
Scorsetti (10.3346/jkms.2016.31.11.1742_ref10) 2011; 6
Vieillevigne (10.3346/jkms.2016.31.11.1742_ref1) 2015; 31
Kim (10.3346/jkms.2016.31.11.1742_ref14) 2015; 67
Hussein (10.3346/jkms.2016.31.11.1742_ref29) 2013; 14
Chung (10.3346/jkms.2016.31.11.1742_ref15) 2014; 25
Jursinic (10.3346/jkms.2016.31.11.1742_ref20) 2010; 37
10.3346/jkms.2016.31.11.1742_ref17
Lee (10.3346/jkms.2016.31.11.1742_ref6) 2006; 17
10.3346/jkms.2016.31.11.1742_ref18
Shim (10.3346/jkms.2016.31.11.1742_ref25) 2012; 23
Hussein (10.3346/jkms.2016.31.11.1742_ref28) 2013; 109
Gloi (10.3346/jkms.2016.31.11.1742_ref19) 2011; 12
Kragl (10.3346/jkms.2016.31.11.1742_ref12) 2011; 21
Bailey (10.3346/jkms.2016.31.11.1742_ref24) 2012; 13
Herzen (10.3346/jkms.2016.31.11.1742_ref30) 2007; 52
22380368 - Med Phys. 2012 Mar;39(3):1351-6
20888199 - Z Med Phys. 2011 May;21(2):91-101
26401138 - Radiol Oncol. 2015 Aug 21;49(3):307-13
21587184 - J Appl Clin Med Phys. 2011 Apr 04;12(2):3367
20632595 - Med Phys. 2010 Jun;37(6):2837-46
21081873 - J Appl Clin Med Phys. 2010 Sep 01;11(4):3164
24100148 - Radiother Oncol. 2013 Dec;109(3):370-6
21587169 - J Appl Clin Med Phys. 2011 Jan 05;12 (2):3251
16475779 - Med Phys. 2005 Dec;32(12):3793-800
22766944 - J Appl Clin Med Phys. 2012 Jul 05;13(4):3736
26699585 - J Appl Clin Med Phys. 2015 Nov 08;16(6):5728
21167659 - Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1220-7
21092163 - Radiat Oncol. 2010 Nov 22;5:110
25598980 - J Med Radiat Sci. 2014 Dec;61(4):261-266
26095758 - Phys Med. 2015 Nov;31(7):720-5
23751395 - Phys Med. 2014 Mar;30(2):184-90
17264380 - Phys Med Biol. 2007 Feb 21;52(4):1197-208
20305334 - Phys Med Biol. 2010 Apr 21;55(8):2155-66
21452698 - Med Phys. 2011 Feb;38(2):612-21
17712302 - J Appl Clin Med Phys. 2007 Jul 17;8(3):2448
21910868 - Radiat Oncol. 2011 Sep 12;6:113
24257288 - J Appl Clin Med Phys. 2013 Nov 04;14(6):4460
12945975 - Med Phys. 2003 Aug;30(8):2089-115
References_xml – volume: 30
  start-page: 184
  year: 2014
  ident: 10.3346/jkms.2016.31.11.1742_ref26
  publication-title: Phys Med
  doi: 10.1016/j.ejmp.2013.05.004
– volume: 55
  start-page: 2155
  year: 2010
  ident: 10.3346/jkms.2016.31.11.1742_ref9
  publication-title: Phys Med Biol
  doi: 10.1088/0031-9155/55/8/003
– volume: 49
  start-page: 307
  year: 2015
  ident: 10.3346/jkms.2016.31.11.1742_ref7
  publication-title: Radiol Oncol
  doi: 10.1515/raon-2015-0021
– volume: 67
  start-page: 1672
  year: 2015
  ident: 10.3346/jkms.2016.31.11.1742_ref14
  publication-title: J Korean Phys Soc
  doi: 10.3938/jkps.67.1672
– ident: 10.3346/jkms.2016.31.11.1742_ref18
– volume: 52
  start-page: 1197
  year: 2007
  ident: 10.3346/jkms.2016.31.11.1742_ref30
  publication-title: Phys Med Biol
  doi: 10.1088/0031-9155/52/4/023
– volume: 11
  start-page: 3164
  year: 2010
  ident: 10.3346/jkms.2016.31.11.1742_ref23
  publication-title: J Appl Clin Med Phys
  doi: 10.1120/jacmp.v11i4.3164
– volume: 23
  start-page: 33
  year: 2012
  ident: 10.3346/jkms.2016.31.11.1742_ref25
  publication-title: Korean J Med Phys
– volume: 12
  start-page: 3367
  year: 2011
  ident: 10.3346/jkms.2016.31.11.1742_ref31
  publication-title: J Appl Clin Med Phys
– volume: 22
  start-page: 61
  year: 2011
  ident: 10.3346/jkms.2016.31.11.1742_ref5
  publication-title: Korean J Med Phys
– volume: 8
  start-page: 2448
  year: 2007
  ident: 10.3346/jkms.2016.31.11.1742_ref22
  publication-title: J Appl Clin Med Phys
– volume: 6
  start-page: 113
  year: 2011
  ident: 10.3346/jkms.2016.31.11.1742_ref10
  publication-title: Radiat Oncol
  doi: 10.1186/1748-717X-6-113
– volume: 38
  start-page: 612
  year: 2011
  ident: 10.3346/jkms.2016.31.11.1742_ref27
  publication-title: Med Phys
  doi: 10.1118/1.3533900
– volume: 32
  start-page: 3793
  year: 2005
  ident: 10.3346/jkms.2016.31.11.1742_ref2
  publication-title: Med Phys
  doi: 10.1118/1.2134929
– volume: 80
  start-page: 1220
  year: 2011
  ident: 10.3346/jkms.2016.31.11.1742_ref11
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2010.10.002
– volume: 17
  start-page: 131
  year: 2006
  ident: 10.3346/jkms.2016.31.11.1742_ref6
  publication-title: Korean J Med Phys
– volume: 39
  start-page: 1351
  year: 2012
  ident: 10.3346/jkms.2016.31.11.1742_ref16
  publication-title: Med Phys
  doi: 10.1118/1.3685461
– volume: 13
  start-page: 3736
  year: 2012
  ident: 10.3346/jkms.2016.31.11.1742_ref24
  publication-title: J Appl Clin Med Phys
  doi: 10.1120/jacmp.v13i4.3736
– volume: 12
  start-page: 3251
  year: 2011
  ident: 10.3346/jkms.2016.31.11.1742_ref19
  publication-title: J Appl Clin Med Phys
  doi: 10.1120/jacmp.v12i2.3251
– volume: 109
  start-page: 370
  year: 2013
  ident: 10.3346/jkms.2016.31.11.1742_ref28
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2013.08.048
– volume: 14
  start-page: 4460
  year: 2013
  ident: 10.3346/jkms.2016.31.11.1742_ref29
  publication-title: J Appl Clin Med Phys
  doi: 10.1120/jacmp.v14i6.4460
– volume: 21
  start-page: 91
  year: 2011
  ident: 10.3346/jkms.2016.31.11.1742_ref12
  publication-title: Z Med Phys
  doi: 10.1016/j.zemedi.2010.07.003
– ident: 10.3346/jkms.2016.31.11.1742_ref17
– volume: 16
  start-page: 5728
  year: 2015
  ident: 10.3346/jkms.2016.31.11.1742_ref13
  publication-title: J Appl Clin Med Phys
  doi: 10.1120/jacmp.v16i6.5728
– volume: 37
  start-page: 2837
  year: 2010
  ident: 10.3346/jkms.2016.31.11.1742_ref20
  publication-title: Med Phys
  doi: 10.1118/1.3431994
– volume: 25
  start-page: 210
  year: 2014
  ident: 10.3346/jkms.2016.31.11.1742_ref15
  publication-title: Prog Med Phys
  doi: 10.14316/pmp.2014.25.4.210
– volume: 31
  start-page: 720
  year: 2015
  ident: 10.3346/jkms.2016.31.11.1742_ref1
  publication-title: Phys Med
  doi: 10.1016/j.ejmp.2015.05.016
– volume: 30
  start-page: 2089
  year: 2003
  ident: 10.3346/jkms.2016.31.11.1742_ref3
  publication-title: Med Phys
  doi: 10.1118/1.1591194
– volume: 5
  start-page: 110
  year: 2010
  ident: 10.3346/jkms.2016.31.11.1742_ref21
  publication-title: Radiat Oncol
  doi: 10.1186/1748-717X-5-110
– volume: 64
  start-page: 1207
  year: 2014
  ident: 10.3346/jkms.2016.31.11.1742_ref4
  publication-title: J Korean Phys Soc
  doi: 10.3938/jkps.64.1207
– volume: 61
  start-page: 261
  year: 2014
  ident: 10.3346/jkms.2016.31.11.1742_ref8
  publication-title: J Med Radiat Sci
  doi: 10.1002/jmrs.78
– reference: 21587184 - J Appl Clin Med Phys. 2011 Apr 04;12(2):3367
– reference: 16475779 - Med Phys. 2005 Dec;32(12):3793-800
– reference: 17712302 - J Appl Clin Med Phys. 2007 Jul 17;8(3):2448
– reference: 22380368 - Med Phys. 2012 Mar;39(3):1351-6
– reference: 26401138 - Radiol Oncol. 2015 Aug 21;49(3):307-13
– reference: 20888199 - Z Med Phys. 2011 May;21(2):91-101
– reference: 21167659 - Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1220-7
– reference: 23751395 - Phys Med. 2014 Mar;30(2):184-90
– reference: 21452698 - Med Phys. 2011 Feb;38(2):612-21
– reference: 22766944 - J Appl Clin Med Phys. 2012 Jul 05;13(4):3736
– reference: 21092163 - Radiat Oncol. 2010 Nov 22;5:110
– reference: 21081873 - J Appl Clin Med Phys. 2010 Sep 01;11(4):3164
– reference: 24100148 - Radiother Oncol. 2013 Dec;109(3):370-6
– reference: 20632595 - Med Phys. 2010 Jun;37(6):2837-46
– reference: 26699585 - J Appl Clin Med Phys. 2015 Nov 08;16(6):5728
– reference: 24257288 - J Appl Clin Med Phys. 2013 Nov 04;14(6):4460
– reference: 21910868 - Radiat Oncol. 2011 Sep 12;6:113
– reference: 17264380 - Phys Med Biol. 2007 Feb 21;52(4):1197-208
– reference: 20305334 - Phys Med Biol. 2010 Apr 21;55(8):2155-66
– reference: 21587169 - J Appl Clin Med Phys. 2011 Jan 05;12 (2):3251
– reference: 25598980 - J Med Radiat Sci. 2014 Dec;61(4):261-266
– reference: 26095758 - Phys Med. 2015 Nov;31(7):720-5
– reference: 12945975 - Med Phys. 2003 Aug;30(8):2089-115
SSID ssj0025523
Score 2.1628025
Snippet The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1742
SubjectTerms Algorithms
Bone Neoplasms - radiotherapy
Humans
Lung Neoplasms - radiotherapy
Male
Original
Prostatic Neoplasms - radiotherapy
Quality Assurance, Health Care
Radiometry - instrumentation
Radiometry - methods
Radiosurgery
Radiotherapy Dosage
Retrospective Studies
의학일반
Title Comparison of Dosimetric Performance among Commercial Quality Assurance Systems for Verifying Pretreatment Plans of Stereotactic Body Radiotherapy Using Flattening-Filter-Free Beams
URI https://www.ncbi.nlm.nih.gov/pubmed/27709851
https://www.proquest.com/docview/1834994850
https://pubmed.ncbi.nlm.nih.gov/PMC5056205
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002164548
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Korean Medical Science, 2016, 31(11), 221, pp.1742-1748
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lj9MwELaWRUJcEG_KozKIq1ESv9IDQuxCtAsqWgFFe7MSx4aobQJpK9Efxv9jxkkDRbvilEPsWMmM7fkynu8j5LmDoHiiY8e85QkTEx6z1JaSuVLFTnvYYoJo3_SDOpmJd-fy_IDsNFv7D7i6ENqhntSsXbz4-WP7Cib8S0ScHDOU8yUSb8cKACgsAXhGBxblq7A3aZyqUzHkFSB-TnhXQHdpT6QH1jqapDLe26uu1K2_KAz99zTlX9tTdpPc6ONK-rpzhFvkwNW3ybVpnzm_Q34dD4KDtPH0TbOqliimZenZn9IBGqSHKBaNoBATPK-j2NhSsOKmDU16inMKfegXcN9QJ0XPWjccWacohLTCUT6B0VyzDnVY9Kgpt_RjXlZ9zdeWhuMKNFsgxSf-nmFZhbl7lrXO0SOXL1d3ySx7-_n4hPWSDcwKkayZtM6nspReleAEXggLEFvqvHBOK_CEMvaRLwrhODhJrnU-QYIxq5T1iH0Sfo8c1k3tHhCaF567yOnEFkrIPC18XFpbxErm3kaWjwjfGcfYns8cZTUWBnANWtegdQ1a1_AYkI5B644IG3p97_g8_tP-GdjdzG1lkIgbr18bM28NwI1TEyc6VSIakac7tzAwOzHlkteu2awMLJgAKUUqoc39zk2GYXdeNiJ6z4GGBjjg_p26-hYYwEPYGsmHlz7zEbmOL9IVTT4mh-t2455A9LQuxoAbTt-Pw7-HcZgcvwGlSh0g
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+Dosimetric+Performance+among+Commercial+Quality+Assurance+Systems+for+Verifying+Pretreatment+Plans+of+Stereotactic+Body+Radiotherapy+Using+Flattening-Filter-Free+Beams&rft.jtitle=Journal+of+Korean+medical+science&rft.au=Chung%2C+Jin+Beom&rft.au=Kang%2C+Sang+Won&rft.au=Eom%2C+Keun+Yong&rft.au=Song%2C+Changhoon&rft.date=2016-11-01&rft.eissn=1598-6357&rft.volume=31&rft.issue=11&rft.spage=1742&rft_id=info:doi/10.3346%2Fjkms.2016.31.11.1742&rft_id=info%3Apmid%2F27709851&rft.externalDocID=27709851
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-8934&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-8934&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-8934&client=summon